Immune therapy trial aims to shrink colon tumors before surgery
NCT ID NCT06830239
Summary
This early study is testing whether two doses of an immunotherapy drug called dostarlimab can help shrink colon tumors before surgery. Researchers will give the drug to 10 patients with stage III colon cancer and study how their tumors and blood change in response. The main goal is to understand which patients might benefit from this approach, though it's not yet proven to improve outcomes.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLON CANCER STAGE III are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
UZLeuven
RECRUITINGLeuven, 3000, Belgium
Contact
Conditions
Explore the condition pages connected to this study.